Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1141 to 1155 of 1315 results for long term conditions

  1. Transition in special groups: looked-after young people:- What is the most effective way of supporting care leavers in transition from children's to adults' health services?

    birth parents in the management of childhood-onset long-term physical and mental health conditions is...

    Research recommendation
    Published
    21 March 2016

  2. Dapagliflozin for treating chronic heart failure with reduced ejection fraction (TA679)

    Evidence-based recommendations on dapagliflozin (Forxiga) for symptomatic chronic heart failure with reduced ejection fraction in adults.

    Technology appraisal guidance
    Published
    24 February 2021
    View recommendations

    Sections for TA679

  3. Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy (TA788)

    Evidence-based recommendations on avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy in adults.

    Technology appraisal guidance
    Published
    11 May 2022
    View recommendations

    Sections for TA788

  4. Preventing excess winter deaths and illness associated with cold homes (QS117)

    This quality standard covers reducing the health risks (including preventable deaths) associated with cold homes. It includes identifying people at risk who are particularly vulnerable to the cold, such as young children, older people, and people with cardiovascular disease or mental health problems. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    4 March 2016
    View quality statements

    Sections for QS117

  5. Lutetium-177 vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments (TA930)

    Evidence-based recommendations on lutetium-177 vipivotide tetraxetan (Pluvicto) for treating prostate-specific membrane antigen-positive hormone-relapsed metastatic prostate cancer after 2 or more treatments in adults.

    Technology appraisal guidance
    Published
    15 November 2023
    View recommendations

    Sections for TA930

  6. Tools for case identification for cognitive impairment in criminal justice system populations:- What are the reliable and valid tools to identify cognitive impairment among people in contact with the criminal justice system (including people who have experienced physical trauma, neurodevelopmental disorders or other acquired cognitive impairment)?

    of, for example, traumatic brain injury, a stroke or other neurological conditions. Experts in this area have suggested that...

    Research recommendation
    Published
    16 May 2017

  7. Bedwetting in under 19s (CG111)

    This guideline covers assessing and treating bedwetting in people aged under 19. It aims to reduce bedwetting and the distress this causes by explaining what to ask in an assessment, what advice to provide, and which treatments are effective.

    Clinical guideline
    Published
    27 October 2010
    View recommendations

    Sections for CG111

  8. trublood-prostate for triaging and diagnosing people with prostate cancer symptoms (MIB268)

    NICE has developed a medtech innovation briefing (MIB) on trublood-prostate for triaging and diagnosing people with prostate cancer symptoms .

    Medtech innovation briefing
    Published
    13 July 2021

  9. Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (TA217)

    Evidence-based recommendations on donepezil (Aricept), galantamine (Reminyl), rivastigmine (Exelon) and memantine (Ebixa) for treating Alzheimer's disease in adults.

    Technology appraisal guidance
    Last updated
    20 June 2018
    View recommendations

    Sections for TA217

  10. KardiaMobile for detecting atrial fibrillation (HTG606)

    Evidence-based recommendations on KardiaMobile for detecting atrial fibrillation.

    HealthTech guidance
    Last updated
    25 July 2023
    View recommendations

    Sections for HTG606

  11. DOAC Dipstick for detecting direct oral anticoagulants (MIB248)

    NICE has developed a medtech innovation briefing (MIB) on DOAC Dipstick for detecting direct oral anticoagulants .

    Medtech innovation briefing
    Published
    2 February 2021

  12. Evidence on the safety and efficacy of intramedullary distraction for upper limb lengthening is inadequate in quantity and quality. But because this is a rare condition with limited alternative treatments, the procedure can be considered as long as special arrangements for clinical governance, consent, and audit or research are in place. Find out what special arrangements mean on the NICE interventional procedures guidance page. Further research, which could be registry data, should report details of patient  selection, device selection, technique used, procedural outcomes, long-term  outcomes including quality of life, the need for repeat interventions or surgery and complication rates.

    quality. But because this is a rare condition with limited alternative treatments, the procedure can be considered as long...

    Research recommendation
    Published
    11 May 2022

  13. S-Cath System for suprapubic catheterisation (MIB68)

    NICE has developed a medtech innovation briefing (MIB) on the S-Cath System for suprapubic catheterisations

    Medtech innovation briefing
    Published
    10 June 2016

  14. Migalastat for treating Fabry disease (HST4)

    Evidence-based recommendations on migalastat (Galafold) for treating Fabry disease in people over 16.

    Highly specialised technologies guidance
    Published
    22 February 2017
    View recommendations

    Sections for HST4

  15. Compression products for treating venous leg ulcers: late-stage assessment (HTG758)

    Late-stage assessment (LSA) guidance on compression products for treating venous leg ulcers.

    HealthTech guidance
    Published
    27 August 2025
    View recommendations

    Sections for HTG758